Drug-induced gingival enlargement – Oral implications for prescribing physicians
DOI:
https://doi.org/10.17159/sadj.v78i03.16273Keywords:
gingival enlargement, t, drug-induced gingival enlargement, gingivitisAbstract
A male patient presented with a main complaint of persistent growth of the upper and lower gingiva that bled easily and resulted
in an inability of maintaining proper oral hygiene. He reports that the growth of the gingiva started approximately three years prior to
consultation in our clinic and is asymptomatic. His medical history revealed that he suffers from epilepsy and was being treated with
a daily anticonvulsant, namely Phenytoin (100mg). Full-mouth non-surgical periodontal therapy was performed and supplemented with an adjunctive chlorhexidine mouth rinse as a chemical plaque control mechanism. Part of the systemic phaseof management of the patient, involved requesting the medical physician change the current epilepsy medication to Epilim®, which was benefi cial in contributing to the resolution of gingival enlargement. Signifi cant reduction in gingival infl ammation and enlargement were achieved with the non-surgical treatment.Corrective surgery therapy was performed to treat those areas of DIGE that had not resolved.
Downloads
References
Thomason JM, Ellis JS, Jovanovski V, et al. Analysis of changes in gingival contour from three-dimensional coordinate data in subjects with drug-induced gingival overgrowth. J Clin Periodontol. 2005;32:1069–1075. DOI: https://doi.org/10.1111/j.1600-051X.2005.00769.x
Wu T, Liao W, Dai N. Three-dimensional statistical model for gingival contour reconstruction. IEEE Trans Biomed Eng. 2015;59:1086–1093. DOI: https://doi.org/10.1109/TBME.2012.2183368
Newman MG, Takei HH, Gingival Pathology: Gingival enlargement. Newman and Carranza’s Clinical Periodontology, 3rd edition 2018. p1523-1559.
Clocheret K, Dekeyser C, Carels C, et al. Idiopathic gingival hyperplasia and orthodontic treatment: a case report. J Orthod. 2003;30:13–19. DOI: https://doi.org/10.1093/ortho/30.1.13
Brown RS, Beaver WT, Bottomley WK. On the mechanism of drug-induced gingival hyperplasia. J Oral Pathol Med. 1991;20:201–209.
Pihlstrom BL. Prevention and treatment of Dilantinassociated gingival enlargement. Compend Suppl. 1990;S506–S510.
Martelli-Junior H, Lemos DP, Silva CO, et al. Hereditary gingival fibromatosis: report of a five-generation family using cellular proliferation analysis. J Periodontol. 2005;76:2299–2305. DOI: https://doi.org/10.1902/jop.2005.76.12.2299
Seymour RA. Calcium channel blockers and gingival overgrowth. Br Dent J. 1991;170:376–379. DOI: https://doi.org/10.1038/sj.bdj.4807564
Hassell TM, Hefti AF. Drug-induced gingival overgrowth: old problem, new problem. Crit Rev Oral Biol Med. 1991;2:103–137. DOI: https://doi.org/10.1177/10454411910020010201
Tipton DA, Fry HR, Dabbous MK. Altered collagen metabolism in nifedipine-induced 4gingival overgrowth. J Periodontal Res. 1994;29:401–409. DOI: https://doi.org/10.1111/j.1600-0765.1994.tb01241.x
Uzel MI, Kantarci A, Hong HH, et al. Connective tissue growth factor in drug-induced gingival overgrowth. J Periodontol. 2001;72:921–931.
Echelard S, Hoyaux D, Hermans M, et al. S100A8 and S100A9 calcium-binding proteins: localization within normal and cyclosporin A-induced overgrowth gingiva. Connect Tissue Res. 2002;43:419–424. DOI: https://doi.org/10.1080/713713464
Saito K, Mori S, Iwakura M, et al. Immunohistochemical localization of transforming growth factor beta, basic fibroblast growth factor and heparan sulphate glycosaminoglycan in gingival hyperplasia induced by nifedipine and phenytoin. J Periodontal Res. 1996;31:545–555. DOI: https://doi.org/10.1111/j.1600-0765.1996.tb00519.x
Kantarci A, Black SA, Xydas CE, et al. Epithelial and connective tissue cell CTGF/CCN2 expression in gingival fibrosis. J Pathol. 2006;210:59–66. DOI: https://doi.org/10.1002/path.2000
Ruby, J., and Barbeau, J. (2002). The buccale puzzle: the symbiotic nature of endogenous infections of the oral cavity. Can J Infect Dis 13, 34–41. DOI: https://doi.org/10.1155/2002/492656
Black SA Jr, Palamakumbura AH, Stan M, et al. Tissuespecific mechanisms for CCN2/CTGF persistence in fibrotic gingiva: interactions between cAMP and MAPK signalling pathways, and prostaglandin E2-EP3 receptor mediated activation of the c-JUN N-terminal kinase. J Biol Chem. 2007;282:15416–15429. DOI: https://doi.org/10.1074/jbc.M610432200
Hassell TM, Page RC, Narayanan AS, et al. Diphenylhydantoin (dilantin) gingival hyperplasia: druginduced abnormality of connective tissue. Proc Natl Acad Sci USA. 1976;73:2909–2912. DOI: https://doi.org/10.1073/pnas.73.8.2909
Brown RS, Beaver WT, Bottomley WK. On the mechanism of drug-induced gingival hyperplasia. J Oral Pathol Med. 1991;20:201–209.
Marshall RI, Bartold PM. A clinical review of drug-induced gingival overgrowths. Aust Dent J. 1999;44:219–232. DOI: https://doi.org/10.1111/j.1834-7819.1999.tb00224.x
Brown RS, Beaver WT, Bottomley WK. On the mechanism of drug-induced gingival hyperplasia. J Oral Pathol Med. 1991;20:201–209. DOI: https://doi.org/10.1111/j.1600-0714.1991.tb00419.x
Uzel MI1, Kantarci A, Hong HH, Uygur C, Sheff MC, Firatli E, Trackman PC. Connective tissue growth factor in drug-induced gingival overgrowth. J Periodontol. 2001 Jul;72(7):921-31. DOI: https://doi.org/10.1902/jop.2001.72.7.921
P.C. Trackman1 and A. Kantarci. Molecular and Clinical Aspects of Drug-induced Gingival Overgrowth. Journal of Dental Research 2015, Vol. 94(4) 540–546 DOI: https://doi.org/10.1177/0022034515571265
Mohammad A . Assaggaf, Alpdogan Kantarci, Siddika S.Sume, Philip C.Trackman. Prevention of Phenytoin-Induced Gingival Overgrowth by Lovastatin in Mice. The American Journal of Pathology Volume 185, Issue 6, June 2015, Pages 1588-1599 DOI: https://doi.org/10.1016/j.ajpath.2015.02.004
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
.png){kind=spacer}